• Something wrong with this record ?

The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations

L. Tichý, T. Freiberger, P. Zapletalová, V. Soška, B. Ravčuková, L. Fajkusová,

. 2012 ; 223 (2) : 401-8.

Language English Country Ireland

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Familial hypercholesterolemia (FH), a major risk for coronary heart disease, is predominantly associated with mutations in the genes encoding the low-density lipoprotein receptor (LDLR) and its ligand apolipoprotein B (APOB). RESULTS: In this study, we characterize the spectrum of mutations causing FH in 2239 Czech probands suspected to have FH. In this set, we found 265 patients (11.8%) with the APOB mutation p.(Arg3527Gln) and 535 patients (23.9%) with a LDLR mutation. In 535 probands carrying the LDLR mutation, 127 unique allelic variants were detected: 70.1% of these variants were DNA substitutions, 16.5% small DNA rearrangements, and 13.4% large DNA rearrangements. Fifty five variants were novel, not described in other FH populations. For lipid profile analyses, FH probands were divided into groups [patients with the LDLR mutation (LDLR+), with the APOB mutation (APOB+), and without a detected mutation (LDLR-/APOB-)], and each group into subgroups according to gender. The statistical analysis of lipid profiles was performed in 1722 probands adjusted for age in which biochemical data were obtained without FH treatment (480 LDLR+ patients, 222 APOB+ patients, and 1020 LDLR-/APOB- patients). Significant gradients in i) total cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients) ii) LDL cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients in men and LDLR+patients > APOB+ patients >LDLR-/APOB- patients in women), iii) triglycerides (LDLR-/APOB- patients > LDLR+ patients > APOB+ patients), and iv) HDL cholesterol (APOB+ patients > LDLR-/APOB- patients = LDLR+ patients) were shown. CONCLUSION: Our study presents a large set of Czech patients with FH diagnosis in which DNA diagnostics was performed and which allowed statistical analysis of clinical and biochemical data.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012647
003      
CZ-PrNML
005      
20130410093105.0
007      
ta
008      
130404s2012 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.atherosclerosis.2012.05.014 $2 doi
035    __
$a (PubMed)22698793
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Tichý, Lukáš $u Centre of Molecular Biology and Gene Therapy, University Hospital Brno, Brno, Czech Republic.
245    14
$a The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations / $c L. Tichý, T. Freiberger, P. Zapletalová, V. Soška, B. Ravčuková, L. Fajkusová,
520    9_
$a BACKGROUND: Familial hypercholesterolemia (FH), a major risk for coronary heart disease, is predominantly associated with mutations in the genes encoding the low-density lipoprotein receptor (LDLR) and its ligand apolipoprotein B (APOB). RESULTS: In this study, we characterize the spectrum of mutations causing FH in 2239 Czech probands suspected to have FH. In this set, we found 265 patients (11.8%) with the APOB mutation p.(Arg3527Gln) and 535 patients (23.9%) with a LDLR mutation. In 535 probands carrying the LDLR mutation, 127 unique allelic variants were detected: 70.1% of these variants were DNA substitutions, 16.5% small DNA rearrangements, and 13.4% large DNA rearrangements. Fifty five variants were novel, not described in other FH populations. For lipid profile analyses, FH probands were divided into groups [patients with the LDLR mutation (LDLR+), with the APOB mutation (APOB+), and without a detected mutation (LDLR-/APOB-)], and each group into subgroups according to gender. The statistical analysis of lipid profiles was performed in 1722 probands adjusted for age in which biochemical data were obtained without FH treatment (480 LDLR+ patients, 222 APOB+ patients, and 1020 LDLR-/APOB- patients). Significant gradients in i) total cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients) ii) LDL cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients in men and LDLR+patients > APOB+ patients >LDLR-/APOB- patients in women), iii) triglycerides (LDLR-/APOB- patients > LDLR+ patients > APOB+ patients), and iv) HDL cholesterol (APOB+ patients > LDLR-/APOB- patients = LDLR+ patients) were shown. CONCLUSION: Our study presents a large set of Czech patients with FH diagnosis in which DNA diagnostics was performed and which allowed statistical analysis of clinical and biochemical data.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoproteiny B $x genetika $7 D001055
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a rozdělení chí kvadrát $7 D016009
650    _2
$a dítě $7 D002648
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipoproteinemie typ II $x krev $x diagnóza $x epidemiologie $x genetika $7 D006938
650    _2
$a lineární modely $7 D016014
650    _2
$a lipidy $x krev $7 D008055
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a LDL-receptory $x genetika $7 D011973
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Freiberger, Tomáš $u -
700    1_
$a Zapletalová, Petra $u -
700    1_
$a Soška, Vladimír $u -
700    1_
$a Ravčuková, Barbora $u -
700    1_
$a Fajkusová, Lenka $u -
773    0_
$w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 223, č. 2 (2012), s. 401-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22698793 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130410093334 $b ABA008
999    __
$a ok $b bmc $g 975845 $s 810928
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 223 $c 2 $d 401-8 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
LZP    __
$a Pubmed-20130404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...